Promising patient studies surrounding Retatrutide , specifically the high-dose formulation referred to as ZPHC, reveal a significant effect on body mass loss and related metabolic illnesses . Researchers anticipate that this dual compound, targeting both GLP-1 and GIP pathways , may offer a substantial breakthrough in the approach of excess weight